CM336 (BCMA/CD3 bispecific antibody)

DRUG3 trials

Sponsors

Institute of Hematology & Blood Diseases Hospital, China

Conditions

Multiple Myeloma (MM)POEMS SyndromeRelapsed Refractory Multiple Myeloma (RRMM)

Phase 1

BCMA/CD3 Bispecific Antibody as Bridging Therapy Before CAR-T Cell Infusion in RRMM

Not yet recruitingNCT07407010

Institute of Hematology & Blood Diseases Hospital, ChinaRelapsed Refractory Multiple Myeloma (RRMM)

Start: 2026-06-01End: 2028-05-31Target: 10Updated: 2026-02-12

Sonrotoclax and BCMA Bispecific Antibody in Newly Diagnosed Systemic AL Amyloidosis Based on t(11;14) Genetic Stratification

Not yet recruitingNCT07687004

Institute of Hematology & Blood Diseases Hospital, ChinaMultiple Myeloma (MM)

Start: 2026-08-01End: 2029-08-01Target: 50Updated: 2026-07-07

Phase 2

BCMA/CD3 BsAb Therapy for POEMS Syndrome

Not yet recruitingNCT07115654

Institute of Hematology & Blood Diseases Hospital, ChinaPOEMS Syndrome

Start: 2025-08-10End: 2027-12-01Target: 10Updated: 2025-08-11